AGP Executive Report
Last update: 4 hours agoSleep & Kids: A new explainer warns that snoring isn’t always “harmless,” linking loud snoring in children to sleep problems, irritability, and even ADHD-like behavior. Cardiology Trials: Two separate studies at ESC 2026 add nuance to heart care: POET-II suggests response-tailored antibiotics for serious valve infections can shorten treatment by about a third, but with a higher relapse rate; LAACS-2 finds routine left atrial appendage closure after open-heart surgery doesn’t help everyone, with benefit mainly for high stroke-risk patients. Public Health & Prevention: Swedish-linked research highlights that older adults’ multimorbidity patterns may change how well lifestyle interventions prevent mobility decline. Respiratory Care Market: A market report projects respiratory care devices growth from $23.6B (2025) to $33.6B (2030), driven by conditions like COPD and sleep apnea. Tobacco Harm Reduction: The FDA authorized new JUUL2 vape products, citing higher complete switching away from cigarettes among adults who smoke. Sweden in Focus: Sweden’s Elekta secured a €100M EIB loan to advance cancer and neurological treatments. Health Systems & Equity: A report says most Liberians with kidney disease won’t survive without earlier detection and stronger screening, despite a dialysis center opening in 2022.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
